Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Phase 3
440
about 5.4 years
15–40
226 sites in AK, AL, AR +39
What this study is about
This trial is testing whether adding levocarnitine to standard chemotherapy protects the liver from damage caused by asparaginase, a drug used to treat leukemia and lymphoma. The goal is to see if levocarnitine can reduce severe liver toxicity in patients with ALL, LL, or MPAL.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Levocarnitine
- 2.Quality-of-Life Assessment
- 3.Take Calaspargase Pegol
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
calaspargase pegol, levocarnitine, pegaspargase
oral (Oral Capsule)
Secondary: Incidence of grade >= 3 alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations during induction therapy
diagnostic
Oncology